載入...
A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab‐Treated non‐small Cell Lung Cancer Patients
To assess circulating biomarkers as predictors of antitumor response to atezolizumab (anti‐programmed death‐ligand 1 (PD‐L1), Tecentriq) serum pharmacokinetic (PK) and 95 plasma biomarkers were analyzed in 88 patients with relapsed/refractory non‐small cell lung cancer (NSCLC) receiving atezolizumab...
Na minha lista:
| 發表在: | Clin Pharmacol Ther |
|---|---|
| Main Authors: | , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
John Wiley and Sons Inc.
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6704358/ https://ncbi.nlm.nih.gov/pubmed/30058723 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.1198 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|